BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/26/2017 10:23:06 AM | Browse: 1519 | Download: 2922
Publication Name World Journal of Gastroenterology
Manuscript ID 31467
Country Mexico
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Basic Study
Article Title Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways
Manuscript Source Invited Manuscript
All Author List Erika Hernández-Aquino, Natanael Zarco, Sael Casas-Grajales, Erika Ramos-Tovar, Rosa E Flores-Beltrán, Jonathan Arauz, Mineko Shibayama, Liliana Favari, Víctor Tsutsumi, José Segovia and Pablo Muriel
Funding Agency and Grant Number
Funding Agency Grant Number
National Council of Science and Technology (Conacyt) of Mexico 253037
National Council of Science and Technology (Conacyt) of Mexico 239516
Fellowship from Conacyt 358378
Corresponding Author Pablo Muriel, PhD, Laboratory of Experimental Hepatology, Department of Pharmacology, CINVESTAV-IPN, Av. Instituto Politécnico Nacional 2508, Apartado Postal 14–740, 07000, Mexico City, Mexico. pmuriel@cinvestav.mx
Key Words Fibrosis; Transforming growth factor-β; Naringenin; pSmad3; Smad3; JNK; Nuclear factor kappa; Carbon tetrachloride
Core Tip To study the effect of naringenin (NAR) on carbon tetrachloride (CCl4)-induced chronic liver fibrosis, male Wistar rats were administered 400 mg of CCl4/kg body weight and 100 mg of NAR/kg body weight for 8 wk. NAR prevented necrosis, cholestasis, oxidative stress, collagen accumulation and the increase in MMP activity caused by CCl4 administration. NAR completely prevented the increase in TGF-β, α-SMA, CTGF, Col-1, MMP-13, NF-κB, IL-1 and IL-10 protein levels caused by CCl4 administration and pSmad3 and pJNK activation. In conclusion, NAR prevents CCl4 induced liver fibrosis due to its antioxidant capacity and by inhibiting the TGF-β-Smad3, JNK-Smad3 and NF-κB pathways.
Publish Date 2017-06-26 10:23
Citation Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368
URL http://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm
DOI http://dx.doi.org/10.3748/wjg.v23.i24.4354
Full Article (PDF) WJG-23-4354.pdf
Full Article (Word) WJG-23-4354.doc